Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma - Institut Curie
Article Dans Une Revue Blood Cancer Journal Année : 2024

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma

Beatrice Casadei
Timothy Voorhees
Adam S Kittai
Antonio Gutiérrez
Maria Jose Terol
Monica Mead
Agrima Mian
Brian T Hill
Emmanuel Bachy
Catherine Thieblemont
Steven Le Gouill

Domaines

Cancer
Fichier principal
Vignette du fichier
s41408-024-01183-8.pdf (747.24 Ko) Télécharger le fichier
41408_2024_1183_MOESM1_ESM.pdf (286.21 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04780223 , version 1 (13-11-2024)

Licence

Identifiants

Citer

Rossana Di Staso, Beatrice Casadei, Frederick Locke, Michael D. Jain, Timothy Voorhees, et al.. Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma. Blood Cancer Journal, 2024, 14 (1), pp.197. ⟨10.1038/s41408-024-01183-8⟩. ⟨hal-04780223⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More